I'm a Pathologist. Do Sleep Peptides Work? Why You're Hungry and Exhausted (DSIP, Epitalon, Orexin)

Why do you wake up exhausted? Sleep and hunger run on the same brain circuit, and in this episode I look at what sleep peptides like DSIP and Epitalon actually do. I'm a triple board-certified physician and pathologist, and I went through the published evidence to separate what's proven from what's mostly marketing.

In 2000, researchers found that people with narcolepsy had lost 85 to 95 percent of one tiny population of brain cells. Those cells make a peptide called orexin, and orexin is what holds you awake right now. The same cells respond to whether you've eaten. On August 5, 2026, the FDA approved a drug built on that discovery. Weeks earlier, a peptide named for inducing sleep went before an FDA advisory committee and was turned down. Almost nobody covered it.

Chapters
00:00 The missing brain cells that keep you awake
01:02 Why you feel tired: sleep's brake and accelerator
03:31 Narcolepsy and the discovery of orexin
07:37 Signs of narcolepsy and cataplexy worth knowing
08:19 Do sleep drugs work? Blocking orexin for insomnia
10:11 The new narcolepsy drug: activating orexin
12:29 The evidence ladder for sleep treatments
13:47 DSIP: delta sleep-inducing peptide explained
15:03 Why the DSIP evidence fell apart
17:32 Epitalon, Semax, Selank, and the FDA vote
19:08 What's in the vial: the manufacturing ladder
20:13 What better peptide research would require
21:39 What works for sleep: CBT-I and more
24:48 Peptide hype, my own experience, and safety
25:32 What we know about sleep peptides

If you want the version of this I walk people through alongside metabolic health: getuninflamed.com
Watch on YouTube: @draminhedayat

References
1. de Lecea L, et al. The hypocretins. PNAS. 1998.
2. Sakurai T, et al. Orexins and orexin receptors. Cell. 1998.
3. Nishino S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000.
4. Thannickal TC, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000.
5. Tasali E, et al. Effect of sleep extension on energy intake in adults with overweight. JAMA Intern Med. 2022.
6. Stefanou A, et al. Dual orexin receptor antagonists and sleep: meta-analysis. Sleep Med. 2026.
7. Dauvilliers Y, et al. Oveporexton in narcolepsy type 1. N Engl J Med. 2025.
8. Harel BT, et al. Psychomotor vigilance test threshold in narcolepsy type 1. Ther Innov Regul Sci. 2026.
9. Sun Y, Gao J. Oveporexton: first-in-class orexin receptor 2 agonist. Drug Discov Ther. 2026.
10. Schneider-Helmert D, et al. Effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981.
11. Monti JM, et al. DSIP efficacy in chronic insomniacs. Int J Clin Pharmacol Res. 1987.
12. Bes F, et al. Effects of DSIP on sleep of chronic insomniac patients. Neuropsychobiology. 1992.
13. Araj SK, et al. Overview of Epitalon. Int J Mol Sci. 2025.
14. Izawa S, et al. REM sleep-active MCH neurons and forgetting. Science. 2019.
15. Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia: AASM guideline. J Clin Sleep Med. 2021.
16. FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026 (DSIP/emideltide, Epitalon, Semax).
17. FDA approval of ORZEYFUL (oveporexton), August 5, 2026.

Disclaimer: This episode is general education only. It isn't medical advice and doesn't create a physician-patient relationship. I'm a physician, but I'm not your physician. Talk to a licensed clinician who knows your history and your other prescriptions before you start, stop or change any medication or supplement. The peptides discussed here aren't FDA-approved treatments for insomnia. Products sold outside a regulated pharmaceutical supply chain carry risks of unknown identity, dose, purity and sterility. If you're struggling with sleep, please see a clinician. Sudden or severe daytime sleepiness, especially while driving, is a medical and safety issue.